Introduction: Renal cell carcinoma (RCC) reveals a tendency towards venous invasion in its advanced stages, making clinical management challenging. Survival may be improved following surgery, but is less clear if it applies to patients with metastatic disease at diagnosis. Materials and Methods: Review of clinical files of patients submitted to surgery for RCC at our institution. Results: Twenty-one patients underwent radical nephrectomy and thrombectomy from 2000 to 2017, with a median follow-up of 25 months. Eighteen (85.7%) men and 3 (14.3%) women, with median age of 63 at the time of diagnosis, were included. The thrombus was in the renal vein in 10 (47.6%) patients and had extension to inferior vena cava (IVC) in 11 (52.4%). The level of involvement in IVC was grade II in 4 (19%) cases, grade III in 4 (19%) cases and grade IV in 3 (14.4%) cases. Surgery was successful in all but 1 patient. Ten patients died during the follow-up (47.6%), resulting in a 5-year overall survival of 34.8%. When considering the metastatic population at diagnosis, the overall survival at 5 years was 45.7%. Conclusion: Radical nephrectomy with removal of the venous thrombus remains the preferential treatment for patients with RCC with venous thrombus, even if they have metastatic disease at diagnosis.

Keywords:
Kidney cancer, Renal cell carcinoma, Venous thrombus, Nephrectomy, Thrombectomy
1.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin D, Forman D, Bray F: Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136:E359–E386.
2.
Wein AJ, Kavoussi LR, Partin AW, Peters CA: Campbell’s Urology (ed 11). Malignant Renal Tumors, Elsevier, 2016.
3.
Neves RJ, Zincke H: Surgical treatment of renal cancer with vena cava extension. Br J Urol 1987; 59: 390–395.
4.
Ljungberg B, Albiges L, Bensalah K, Bex A, Hora M, Kuczyk M, Lam T, Marconi L, Merseburger A, Powles T, Staehler M, Volpe A: Guidelines on Renal Cell Carcinoma. European Association of Urology, 2018. http://uroweb.org/guideline/renal-cell-carcinoma/.
5.
Bissada N, Yakout H, Babanouri A, Elsalamony T, Fahmy W, Gunham M, Hull G, Chaudhary U: Long-term experience with management of renal cell carcinoma involving the inferior vena cava. Urology 2003; 61: 89–92.
6.
Blute ML, Leibovich BC, Lohse CM, Cheville JC, Zincke H. The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus. BJU Int 2004; 94: 33–41.
7.
Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H: An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade, and necrosis: the SSIGN score. J Urol 2002; 168: 2395–2400.
8.
Agochukwu N, Shuch B: Clinical management of renal cell carcinoma with venous tumor thrombus. World J Urol 2014; 32: 581–589.
9.
Figlin R, Leibovich B, Stewart G, Negrier S: Adjuvant therapy in renal cell carcinoma: does higher risk for recurrence improve the chance for success? Ann Oncol 2018; 29: 324–331.
10.
Haas N, Manola J, Uzzo R, Flaherty K, Wood C, Kane C, Jewett M, Dutcher J, Atkins M, Pins M, Wilding G, Cella D, Wagner L, Matin S, Kuzel T, Sexton W, Wong Y, Choueiri T, Pili R, Puzanov I, Kohli M, Stadler W, Carducci M, Coomes R, DiPaola R: Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 2016; 387: 2008–2016.
11.
Haas N, Manola J, Dutcher J, Flaherty K, Uzzo R, Atkins M, DiPaola R, Choueiri T: Adjuvant treatment for high-risk clear cell renal cancer: updated results of a high-risk subset of the ASSURE randomized trial. JAMA Oncol 2017; 3: 1249–1252.
12.
Ravaud A, Motzer R, Pandha H, George D, Pantuck A, Patel A, Chang Y, Escudier B, Donskov F, Magheli A, Carteni G, Laguerre B, Tomczak P, Breza J, Gerletti P, Lechuga M, Lin X, Martini J, Ramaswamy K, Casey M, Staehler M, Patard J, S-TRAC Investigators: Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy. N Engl J Med 2016; 375: 2246–2254.
13.
Motzer R, Haas N, Donskov F, Gross-Goupil M, Varlamov S, Kopyltsov E, Lee J, Melichar B, Rini B, Choueiri T, Zemanova M, Wood L, Reaume M, Stenzl A, Chowdhury S, Lim H, McDermott R, Michael A, Bao W, Carrasco-Alfonso M, Aimone P, Voi M, Doehn C, Russo P, Sternberg C, PROTECT Investigators: Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with locally advanced renal cell carcinoma. J Clin Oncol 2017; 35: 3916–3923.
14.
Klatte T, Pantuck A, Riggs S, Kleid M, Shuch B, Zomorodian N, Kabbinavar F, Belldegrun A: Prognostic factors for renal cell carcinoma with tumor thrombus extension. J Urol 2007; 178: 1189–1195.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.